Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881390 | 0.88 | ESR2 (0.47) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL30171269 | 0.85 | ESR2 (0.48) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL7988322 | 0.84 | ESR2 (0.47) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL7986367 | 0.84 | ESR2 (0.47) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL17518804 | 0.83 | HRH3 (0.46) | HPGDSSIGMAR1 | |
| SCHEMBL16217166 | 0.82 | ESR2 (0.52) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL16144644 | 0.81 | HPGDS (0.51) | HPGDSSIGMAR1PDK2 | |
| SCHEMBL17516261 | 0.80 | SIGMAR1 (0.40) | HPGDSSIGMAR1PDK2 | |
| SCHEMBL20792551 | 0.80 | MAPT (0.53) | ESR2MAPTHPGDSNR1H2SLC34A1 | |
| SCHEMBL7975140 | 0.80 | ESR2 (0.44) | ESR2MAPTHPGDSNR1H2SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | ESR2 363/4885MAPT 4800/4885HPGDS 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.